Cretostimogene Grenadenorepvec May be ‘Attractive’ Option for NMIBC
Cretostimogene grenadenorepvec’s efficacy compares favorably with the current nonsurgical standards of care in high-risk, Bacillus Calmette Guerin–unresponsive non-muscle invasive bladder cancer.